Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) (NCT02366884) (2022)

Government Record · Dr. Frank Arguello Cancer Clinic (sponsor) · April 6, 2022

Dr. Frank Arguello Cancer Clinic (sponsor), 2022-04-06: Registry record for a Mexican phase 2 trial of multi-drug 'atavistic chemotherapy' that includes mebendazole among several antiprotozoal agents. It lists 250 planned participants and an unknown status.

nitazoxanide, chloroquine, albendazole, ivermectin, mebendazole, metronidazole, praziquantel, levamisole

n/a

Dr. Frank Arguello Cancer Clinic (sponsor), 2022-04-06: Registry record for a Mexican phase 2 trial of multi-drug 'atavistic chemotherapy' that includes mebendazole among several antiprotozoal agents. It lists 250 planned participants and an unknown status. Record field paraphrased from the intervention list; registry record. Study type: phase 2, single-arm with several drug combinations. N=250 estimated. Country: Mexico. Dose: not stated for mebendazole; the antiprotozoal arm lists albendazole, ivermectin and mebendazole among others. Sponsor: Dr. Frank Arguello Cancer Clinic. Status: UNKNOWN; start 2011-07-26; estimated completion 2023-12-31. hasResults=false. Comparator: none. Weakly relevant because mebendazole is one of several agents and no dose is given. Registry entry; no results posted.